Pharma Journalist -

Zymeworks Inc. announced the initiation of a Phase 2 trial evaluating ZW25 combination therapy and an agreement with Pfizer which advances the study. Zymeworks’ HER2-targeted bispecific…
Read More...

eFFECTOR Therapeutics and Pfizer Inc. announced an exclusive worldwide license and collaboration agreement to develop small-molecule inhibitors of eukaryotic initiation factor 4E…
Read More...

Eli Lilly and Company and Dermira, Inc. announced a definitive agreement for Lilly to acquire Dermira for $18.75 per share, or approximately $1.1 billion, in an all-cash transaction.…
Read More...

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, reported that the previously…
Read More...

Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, and Cellectis, a clinical-stage biopharmaceutical company focused on…
Read More...

SMi Reports: Interactive workshop overview for SMi's 22nd Annual Superbugs & Superdrugs Conference, London in March 2020 SMi’s highly anticipated 22nd Annual Superbugs &…
Read More...

PPD, Inc. (PPD) has expanded its operations and leadership team in China to provide enhanced clinical development, laboratory, regulatory, site conduct, patient access and post-approval…
Read More...

Almirall, S.A. and WuXi Biologics have announced the signing of an agreement. Through this collaboration Almirall embarks on its strategy to develop highly innovative biologic products…
Read More...

Hikma Pharmaceuticals PLC, the multinational generic pharmaceutical company, and Arecor Ltd, the biopharmaceutical company advancing therapies to enable healthier lives, today announce…
Read More...

Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has approved Fiasp (insulin aspart injection) 100 u/mL for use as a new mealtime insulin option for children with…
Read More...